Literature DB >> 10411481

Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study.

S Vassiliou1, A Mucha, P Cuniasse, D Georgiadis, K Lucet-Levannier, F Beau, R Kannan, G Murphy, V Knäuper, M C Rio, P Basset, A Yiotakis, V Dive.   

Abstract

Several phosphinic pseudo-tripeptides of general formula R-XaaPsi(PO(2)-CH(2))Xaa'-Yaa'-NH(2) were synthesized and evaluated for their in vitro activities to inhibit stromelysin-3, gelatinases A and B, membrane type-1 matrix metalloproteinase, collagenases 1 and 2, and matrilysin. With the exception of collagenase-1 and matrilysin, phosphinic pseudo-tripeptides behave as highly potent inhibitors of matrix metalloproteinases, provided they contain in P(1)' position an unusual long aryl-alkyl substituent. Study of structure-activity relationships regarding the influence of the R and Xaa' substituents in this series may contribute to the design of inhibitors able to block only a few members of the matrix metalloproteinase family.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10411481     DOI: 10.1021/jm9900164

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  16 in total

1.  Using fluorogenic peptide substrates to assay matrix metalloproteinases.

Authors:  G B Fields
Journal:  Methods Mol Biol       Date:  2001

Review 2.  Macrocyclic histone deacetylase inhibitors.

Authors:  Sandra C Mwakwari; Vishal Patil; William Guerrant; Adegboyega K Oyelere
Journal:  Curr Top Med Chem       Date:  2010       Impact factor: 3.295

3.  Triple-helical transition state analogues: a new class of selective matrix metalloproteinase inhibitors.

Authors:  Janelle Lauer-Fields; Keith Brew; John K Whitehead; Shunzi Li; Robert P Hammer; Gregg B Fields
Journal:  J Am Chem Soc       Date:  2007-08-02       Impact factor: 15.419

4.  A structural insight into the P1S1 binding mode of diaminoethylphosphonic and phosphinic acids, selective inhibitors of alanine aminopeptidases.

Authors:  Ewelina Węglarz-Tomczak; Łukasz Berlicki; Małgorzata Pawełczak; Bogusław Nocek; Andrzej Joachimiak; Artur Mucha
Journal:  Eur J Med Chem       Date:  2016-04-09       Impact factor: 6.514

5.  Efficient synthesis of Fmoc-protected phosphinic pseudodipeptides: Building blocks for the synthesis of matrix metalloproteinase inhibitors.

Authors:  Manishabrata Bhowmick; Ravinder R Sappidi; Gregg B Fields; Salvatore D Lepore
Journal:  Biopolymers       Date:  2011       Impact factor: 2.505

6.  Selenium-containing analogs of SAHA induce cytotoxicity in lung cancer cells.

Authors:  Nilkamal Karelia; Dhimant Desai; Jeremy A Hengst; Shantu Amin; Sairam V Rudrabhatla; Jong Yun
Journal:  Bioorg Med Chem Lett       Date:  2010-08-27       Impact factor: 2.823

7.  In vitro plasma stability, permeability and solubility of mercaptoacetamide histone deacetylase inhibitors.

Authors:  Roula Konsoula; Mira Jung
Journal:  Int J Pharm       Date:  2008-05-13       Impact factor: 5.875

8.  High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate.

Authors:  Janelle L Lauer-Fields; Dmitriy Minond; Peter S Chase; Pierre E Baillargeon; S Adrian Saldanha; Roma Stawikowska; Peter Hodder; Gregg B Fields
Journal:  Bioorg Med Chem       Date:  2008-03-06       Impact factor: 3.641

9.  Screening of potential a disintegrin and metalloproteinase with thrombospondin motifs-4 inhibitors using a collagen model fluorescence resonance energy transfer substrate.

Authors:  Janelle L Lauer-Fields; Timothy P Spicer; Peter S Chase; Mare Cudic; Gayle D Burstein; Hideaki Nagase; Peter Hodder; Gregg B Fields
Journal:  Anal Biochem       Date:  2007-09-15       Impact factor: 3.365

10.  Synthesis of Fmoc-Gly-Ile Phosphinic Pseudodipeptide: Residue Specific Conditions for Construction of Matrix Metalloproteinase Inhibitor Building Blocks.

Authors:  Manishabrata Bhowmick; Gregg B Fields
Journal:  Int J Pept Res Ther       Date:  2012-12       Impact factor: 1.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.